To date, many cytoprotective drugs have reached the stage of pivotal phase 3 efficacy trials in acute stroke patients. (Table 1 ) Unfortunately, throughout the neuroprotective literature, the phrase "failure to demonstrate efficacy" prevails as a common thread among the many neutral or negative trials, despite the largely encouraging results encountered in preclinical studies. The reasons for this discrepancy are multiple, and have been discussed by Dr. Zivin in his review. Many of the recent trials have addressed deficiencies of the previous ones with more rigorous trial design, including more specific patient selection criteria (ensure homogeneity of stroke location and severity), stratified randomization algorithms (time-totreat), narrowed therapeutic time-window and pharmacokinetic monitoring. Current trials have also incorporated biologic surrogate markers of toxicity and outcome such as drug levels and neuroimaging. Lastly, multi-modal therapies and coupled cytoprotection/reperfusion strategies are being investigated to optimize tissue salvage. This review will focus on individual therapeutic strategies and we will emphasize what we have learned from these trials both in terms of trial design and the biologic effect (or lack thereof) of these agents.
1
The calcium channel antagonist that has undergone the most extensive investigation in stroke is nimodipine. 2 Several randomized controlled clinical studies have conclusively demonstrated the effectiveness of nimodipine in preventing ischemic neurologic deficit and poor outcome secondary to aneurysmal subarachnoid hemorrhage. [3] [4] [5] [6] [7] Prophylactic therapy with nimodipine is now standard treatment in subarachnoid hemorrhage. The usual dose is 60 mg orally every 4 h for 21 days, but a lower dose or a more frequent dosing schedule may be used if hypotension is limiting. Although it is uncertain whether nimodipine has its primary effect in this clinical setting as a cytoprotective drug or as a vasodilator, the use of nimodipine does not result in angiographically evident improvement of vasospasm.
Oral nimodipine has been investigated in ischemic stroke in at least 29 randomized placebo-controlled trials. These studies enrolled patients with time windows ranging from 6 to 48 h, used nimodipine doses between 60 and 240 mg/day, and treated for periods of 14 to 28 days. A few of the earlier studies found a significant difference in mortality and neurologic function in favor of nimodipine therapy 8 -11 ; however, subsequent larger studies and a recent meta-analysis failed to replicate this benefit. 12 Several studies have actually shown a better outcome in the placebo-treated patients, a finding attributed to hypotension induced by both oral and intravenous administration of the drug. [13] [14] [15] The most recent and extensive meta-analysis of 22 calcium antagonist trials, studying over 6,800 patients, failed to demonstrate any beneficial effect of treatment, even in early treatment subgroups (within 12 h of stroke onset) (FIG. 1) . 16 In addition, meta-analysis limited to the "good" quality trials found a statistically significant negative effect of calcium antagonists. In fact, the results from this meta-analysis prompted the premature termination of the Very Early Nimodipine Use in Stroke (VE- NUS) trial that was designed to determine the efficacy of nimodipine administered within 6 h of stroke onset. 17 The interim analysis of 454 patients showed no effect of nimodipine; however, within the ischemic stroke subgroup an increase in poor outcome at 3 months was found in the nimodipine-treated patients [relative risk 1.4, 95% confidence interval (CI) 1.0-2.1] ( Table 2) . Another dihydropyridine calcium channel antagonist, nicardipine, has also been tested in a pilot stroke study. 18 Hypotension was a frequent, dose-related side effect.
The lack of effect, or presence of detrimental effect, of calcium antagonists may be due to the hypotension caused by blocking the vascular smooth muscle cells. Another plausible explanation for the failure of calcium antagonists is that neurotransmitter release is a proximal event in the excitotoxic cascade with immediate effects; therefore, any delay in drug administration prevents its theoretical efficacy in preventing cell necrosis. Delayed or prolonged use of L-type antagonists may actually induce apoptotic cell death since modest increases in calcium inhibit apoptosis. 19 This mechanism may overcome other protective actions of these agents. Glutamate antagonists N-methyl-D-aspartate (NMDA) receptor antagonists were the first class of acute stroke therapeutic agents to proceed from development in the laboratory to testing in humans, employing modern principles of clinical trial design, most important relatively early treatment. The potential utility of NMDA antagonists in stroke was first recognized when it was observed that a hypoxic or ischemic insult results in elevation of brain levels of the excitatory neurotransmitter glutamate. The excitotoxic theory of ischemic brain injury implicates glutamate as a pivotal mediator of cell death via ligand-gated receptors (NMDA and AMPA receptors). The NMDA receptor is a complex ligand-gated ion channel that requires activation by glutamate and glycine, as well as concomitant membrane depolarization to overcome a voltage-dependent block by magnesium ions.
TABLE 2. Results from VENUS Study Subgroup Analyses of Patients with Poor Outcome in Each Group
The complex structure of the NMDA receptor provides multiple sites for therapeutic inhibition. Competitive NMDA antagonists bind directly to the glutamate site of the NMDA receptor to inhibit the action of glutamate. Noncompetitive antagonists block the NMDA-associated ion channel in a use-dependent manner. Other sites on the NMDA receptor susceptible to antagonism include the glycine site and the polyamine site. Prototypes of these competitive and noncompetitive NMDA antagonists have been studied in phase 3 clinical trials for the treatment of stroke.
Selfotel (CGS19755) is a competitive NMDA receptor antagonist that limits neuronal damage in animal stroke models. 20 -22 Selfotel was evaluated in a randomized, double-blind, placebo-controlled, ascending dose phase 2a study to determine its safety and tolerability, and obtain pharmacokinetic and preliminary efficacy data. 23 Patients were treated within 12 h of ischemic hemispheric stroke onset. Non-CNS adverse effects were infrequent and not different between the Selfotel and placebo groups. Neuro-psychiatric adverse experiences were common, dose-related, and lasted an average of 24 h. Symptoms included hallucinations, agitation, confusion, dysarthria, ataxia, delirium, paranoia, and somnolence. Patients experienced mild adverse experiences with Selfotel 1.5 mg/kg; however, when the dose was increased to 2 mg/kg given once or twice, adverse experiences occurred in all patients. Based on these data, phase 3 parallel studies of a single dose of 1.5 mg/kg of Selfotel given within 6 h of the onset of acute hemispheric stroke were begun in the United States and Europe, but were suspended after 31% of planned enrollment because of an unfavorable efficacy/toxicity ratio. 24 Intention-to-treat analyses demonstrated that adverse events were more common and more often neurologic in the Selfotel group (Table 3 ). In addition, the proportion of patients with neurologic progression or decreased arousal was higher in the Selfotel group, as were both 8-and 30-day mortality. There was no difference between Selfotel and placebo in the primary endpoint of functional independence (Table 4) . Although there was no statistical difference in mortality over the entire study, post hoc analysis revealed a statistically significant increase in 8-and 30-day mortality in the Selfotel group (Table 5) .
It may be concluded from these trials that Selfotel is not efficacious as a cytoprotectant and may potentially exert a neurotoxic effect in patients with severe stroke. The Selfotel trials exhibit an important principle of cytoprotectant failure: the narrow therapeutic index. Animal models determined that a plasma level of 40 g/ml Selfotel was cytoprotective. However, the highest tolerated level in human stroke patients was only half of this target cytoprotective concentration (21 g/ml) and even these "subtherapeutic" levels produced marked neurological and psychiatric effects. 25 The noncompetitive NMDA antagonist dextrorphan was also evaluated in a pilot study. 26 Patients were enrolled in this study within 48 h of the onset of hemispheric cerebral infarction. As with Selfotel, adverse effects of dextrorphan occurred in a dose-dependent manner, including agitation, confusion, hallucinations, nystagmus, somnolence, nausea, and vomiting. Hypotension occurred at the highest loading doses (Ͼ200 mg/h), but was not associated with neurologic deterioration. There were no apparent differences in the outcome between placebo patients or low-, medium-, or high-dose dextrorphan patients. Unlike Selfotel, plasma concentrations of dextrorphan were achieved that were comparable to the cytoprotective level determined in cell culture and animal models. At the present time, no further clinical trials of dextrorphan are in progress.
A phase 2a dose escalation and tolerability study of the noncompetitive NMDA antagonist CNS1102 (Cerestat, aptiganel) was reported in patients within 18 h of stroke onset. 27 Side effects observed were hypertension, headache, sedation, nausea, vomiting, disorientation, and paresthesias. Of 94 patients, 10 had mild to moderate agitation or confusion, which seemed to be less severe than the side effects seen with Selfotel and dextrorphan.
A multicenter placebo-controlled, double-blind randomized trial was then conducted to evaluate the safety and tolerability of escalating doses of Cerestat, and to determine the pharmacokinetic properties of the drug. 28 Forty-six patients with ischemic carotid artery territory stroke [National Institute of Health Stroke Scale (NIHSS) score [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] were enrolled within 24 h of symptom onset. In part A, patients were randomized 3:1 to a single bolus of Cerestat or placebo. Doses up to 6 mg were well tolerated; however, 7.5 mg caused more frequent and more severe side effects (sedation, hallucination, confusion). In phase B, a constant, optimal bolus dose (6 mg as determined in part A) was followed by a 6-to 12-h continuous infusion of 1 mg/hr. However, the dosing regimen in part B was abandoned due to hypertension and severe sedation. Therefore, a lower dose regimen was adopted (4.5 mg bolus, followed by 0.75 mg/hr infusion). The lower dose regimen successfully achieved the target cytoprotective plasma concentration Ͼ10 ng/ml as determined in animal studies. This dose was associated with moderately increased systolic blood pressure (ϳ30 mmHg), which was responsive to antihypertensive agents, and neurologic adverse experiences (mild sedation and confusion) that were easily tolerated by patients. However, no suggestion of treatment effect was found between the groups.
Based on these results, a nested phase 2/phase 3 study was performed evaluating low-dose and high-dose Cerestat regimens compared to placebo. 29 Patients with clinical diagnosis of ischemic stroke were randomized to 1 of 3 treatment arms within 6 h of symptom onset. Phase 3 enrollment was terminated early, based on analysis of the phase 2 data that revealed an increase in mortality within the Cerestat cohort. Analysis of available phase 3 data (628 patients) showed no difference in 90-day outcome measured by modified Rankin Scale (mRS) among the 3 groups. The difference in 90-day mortality was not significant; however, there was a marginally increased mortality at 120 days in the high-dose group. Other secondary analyses showed a significant difference favoring placebo over high-dose Cerestat in multiple outcome measures. Based on the evidence, Cerestat is not efficacious within 6 h of onset and may be harmful at higher doses.
Magnesium (Mg 2ϩ ) is theoretically an ideal neuroprotectant based upon its diverse mechanisms of action, low cost, ease of administration, wide therapeutic index, good blood-brain barrier (BBB) permeability, and established safety profile. Mg 2ϩ ions endogenously function as a physiologic voltage-dependent block of the NMDA receptor ion channel and inhibitor of ischemia-induced glutamate release. 30 In addition to these anti-excitotoxic actions, Mg 2ϩ antagonizes voltage-gated Ca 2ϩ channels of all types, promotes vasodilation, inhibits the inflam- matory response, and calcium-mediated activation of intracellular enzymes. 31 Preclinical models show that MgSO4 reduces infarct volume with a dose-response relationship demonstrated within easily achieved serum levels (1.49 mmol/l) even 6 h after stroke. 32 This model refreshingly mimics the clinical reality in which patients present for treatment h after the onset of ischemia. However, the benefit of Mg 2ϩ has only been shown in some labs in some models.
Several pilot studies have already demonstrated the safety and tolerability of intravenous Mg 2ϩ in acute ischemic stroke patients. 33, 34 Administration of MgSO4 as loading dose followed by a 24-h continuous infusion has been studied in over 3,000 stroke patients within 48 h with no significant adverse events. The majority of these studies have not revealed significant hypotension or hyperglycemia that were experienced in some preclinical evaluations of MgCl. 35 The majority of reported adverse events were the expected complications of the initial stroke and did not differ from placebo. A dose optimization study identified a dose (16 mmol bolus, 24-h continuous infusion of 65 mmol) capable of achieving the minimum neuroprotective serum levels in all patients while producing no adverse events. 34 A systematic review of four phase 2 clinical trials disclosed an insignificant, 8% absolute reduction in the combined endpoint of death or functional dependence. 30 One of the largest impediments to translating experimental efficacy to a clinical reality is the delayed administration of potentially cytoprotective therapies. Ongoing trials of magnesium administration have been designed to specifically address this issue. The FAST-MAG (Field Administration of Stroke Therapy-Magnesium) pilot study was an open-label evaluation of the safety and feasibility of paramedic-initiated magnesium therapy to stroke patients identified in the field by the Los Angeles Prehospital Stroke Screen (LAPSS). 36 The average time to treatment was only 23 min from arrival of Emergency Medical Services on the scene, and median time to treatment from symptom onset was 100 min with 25% of patients treated within 1 h, the shortest onset-to-treatment interval reported to date. Greater than two-thirds of patients had a good functional outcome.
Currently, a phase 3 multicenter, randomized, placebocontrolled trial will soon begin enrolling patients to evaluate the efficacy of field-administered, hyperacute Mg 2ϩ therapy within 2 h of stroke onset. Additionally, the IMAGES Study Group is conducting a large phase 3 trial of MgSO4 administered within 12 h of onset designed with sufficient statistical power to detect only a 5.5% absolute difference in death or dependence. Rigorous trial design has employed a randomization algorithm that maintains balanced group-allocation of patients based on prognostic variables including age, laterality of stroke, time-to-randomization, and Oxfordshire Community Stroke Project classification. This study represents the single largest cytoprotective study to date and has enrolled over 1,800 patients, nearly half of which have been treated within 6 h of onset. An IMAGES sub-study will employ magnetic resonance imaging (MRI) as a biological surrogate for neuroprotective efficacy.
In summary, while preclinical studies of competitive and noncompetitive NMDA antagonists suggest that they can effectively protect penumbral regions, clinical studies have thus far been disappointing. Trial design, lacking forced time-to-treatment stratification, and patient selection criteria for stroke homogeneity, may have contributed to these results. As with calcium antagonists, achieving neuroprotection by blocking glutamate-induced damage means interrupting events that are triggered almost immediately after the onset of ischemia so that the time to treatment from onset must be brief. This narrow time-window, seen in all animal studies, was ignored in all clinical trials of these drugs except for the FAST-MAG trial. The negative clinical results with NMDA antagonists may also be attributed to the doselimiting phencyclidine-like side effects preventing achievement of therapeutic brain levels. An understanding of the clinically apparent neurotoxicity of NMDA antagonists involves a condition described as NMDA receptor hypofunction. NMDA antagonists have been shown to induce large vacuoles within the adult rodent brain that may signify irreversible damage. 37 Recent molecular experiments have uncovered that an indirect complex network disturbance is responsible for the NMDA receptor hypofunction. Finally, a model of immature rodents demonstrates that administration of NMDA antagonists during the period of synaptogenesis triggers diffuse apoptotic degeneration throughout the brain. 38 These complex interactions indicate the potential problems with using drugs that target specific neurotransmitter function. Attempts have been made to develop strategies inhibiting glutamate-induced damage while avoiding the toxicity profile of direct NMDA receptor antagonism. Clinical trials of these and more "downstream" agents will now be discussed.
Agents acting indirectly on glutamate
Eliprodil, an antagonist of the polyamine site of the NMDA receptor, has been evaluated in phase 2 and phase 3 trials of acute stroke patients. However, these data remain unpublished and further investigation has stopped due to an unsatisfactory risk/benefit ratio.
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GV150526 (gavestinel) is a novel glycine site antagonist at the NMDA receptor complex, which exhibits neuroprotective effects in experimental stroke models at established plasma levels (10 to 30 g/ml) with a paucity of toxicity and an extended time-window (6 h). 40 A phase 2 randomized, placebo-controlled, two-part ascending dose trial evaluated the safety, tolerability, and pharmacokinetics of a gavestinel loading dose followed by continuous infusion within 12 h of stroke onset. 41 The first part involved administration of escalating loading doses to determine the maximal tolerated dose of gavestinel. In the second part, the maximum tolerated loading dose from part one (800 mg) was followed by five maintenance infusions every 12 h. GV150526 produced no increased hemodynamic or neuro-psychiatric events compared to placebo. No consistently reported or doserelated side effects, serious adverse events or mortality were attributed to drug administration. Mild anemia and asymptomatic, transient dose-dependent elevations in liver function tests were observed. Significantly higher serum glucose levels were observed in patients receiving maintenance gavestinel and the degree of hyperglycemia was correlated to the volume of dextrose diluent used for infusion. All loading dose regimens easily achieved plasma concentrations exceeding the predicted therapeutic levels from animal studies, and maintenance infusions of 200 or 400 mg b.i.d. sustained this neuroprotective level. An 800-mg loading dose followed by five 200-mg infusions twice daily was identified as the optimal dosage to be used for phase 3 efficacy studies.
Subsequently, two large phase 3 randomized placebocontrolled, double-blind trials failed to demonstrate the efficacy of gavestinel despite adequate powering to detect even small differences. The GAIN Americas trial randomized 1,367 patients within 6 h of stroke onset and concomitant treatment with intravenous TPA was allowed in eligible patients. 42 Patients were stratified at randomization by age and initial stroke severity. Mean NIHSS was 12 and median time to treatment was 5.2 h. No statistically significant difference in mortality or 3-month outcome measures [Barthel Index (BI), mRS, or NIHSS score] was found among the groups (FIG. 2) . Subgroup analysis revealed a significant treatment benefit in younger patients with mild stroke (Յ 75 years, NIHSS 2-5) that persisted even after adjustment for age, baseline NIHSS, use of TPA, time to treat, and stroke subtype. However, no treatment effect was seen in either the TPA-treated patients (n ϭ333) or those treated within 4 h of onset (n ϭ 244).
The GAIN International trial recruited 1,804 patients within 6 h of stroke onset and used the same dosing regimen and stratified randomization schema. 43 The primary efficacy measure, survival combined with 3-month, BI, was analyzed in only the ischemic stroke population. Secondary endpoints included BI, NIHSS score, mRS, death within 3 months, and global statistical test of combined neurological status at 3 months. Gavestinel had no effect on primary or secondary outcome measures compared with placebo when baseline NIHSS score and age were included as covariates in proportional odds models. Minor adverse events were seen more commonly in the gavestinel group, but no significant differences were found in serious adverse events (FIG. 3) .
The neutral results of the large gavestinel trials are disconcerting for several reasons. First, the clinical testing closely mimicked the experimental models exhibiting neuroprotection even after 6 h of ischemia. Second, these trials incorporated an adequate number of patients to exclude a clinically significant benefit of gavestinel, a point that has been used to criticize previous trials. Additionally, these trials appropriately stratified patients according to baseline stroke severity and age, factors that may otherwise cause imbalances within treatment and placebo groups and produce confounding results. Lastly, "supra-therapeutic" neuroprotective levels were achieved producing only minimal and tolerable side effects. Therefore, unlike other modulators of glutamate activity, gavestinel doses were not limited by intolerability of "therapeutic" doses. The cause of the neutral results with gavestinel remains to be explained. It is possible that the time window to effectively antagonize glutamate is simply less than 6 h, or that the neuroprotective benefit of infarct size reduction in animals does not translate into improved functional outcome measured in clinical trials. Just as likely, however, expectations with gavestinel were over-inflated because only positive preclinical results were published (it is common that negative results in animal studies go unreported). Mild beneficial effects were only seen in carefully standardized stroke models that do not reflect the heterogeneity of stroke patients where more robust efficacy would be needed to achieve clinical significance.
Blockade of glutamate-activated AMPA receptors represents another target of cytoprotection with several advantages over NMDA receptor antagonism including potential protection of both cortical gray matter and subcortical white matter regions, and reduction of secondary activation of NMDA receptor and voltage-gated calcium channels. One promising AMPA antagonist, YM872, has demonstrated reduced infarct volume comparable to NMDA receptor antagonists in animal models. 44 Enrollment has just been terminated prematurely in two concurrent YM872 clinical trials, the ARTIST (AMPA Receptor Antagonist Treatment in Ischemic Stroke) trials, based on an interim futility analysis. These multicenter, randomized, double-blind, placebo-controlled trials were designed to "fill in the gaps" left by past neuroprotection trials-combination of reperfusion and neuroprotection strategies, and use of a biologic marker of efficacy. ARTISTϩ compared the efficacy of YM872 plus TPA to that of placebo plus TPA. Preclinical data have demonstrated that co-administration of TPA and YM872 within 2 h of stroke imparts a greater degree of cytoprotection than either agent alone. 45 Patients with acute hemispheric ischemic stroke and a moderate-to-severe deficit treated with standard protocol TPA were eligible. The planned enrollment was 600 patients; over 400 patients were enrolled. The drug was started before the end of TPA infusion and continued for 24 h. Primary efficacy/outcome measures included neurological function and disability scales.
The second trial, ARTIST MRI, evaluated the safety and potential efficacy of YM872 administered to stroke patients within 6 h of onset using MRI as a surrogate marker of outcome. Baseline ischemic lesion volume on diffusion-weighted imaging was compared to final lesion volume on T2-weighted MRI to detect effect of YM872 on lesion growth. The abandonment of these very welldesigned trials is disappointing. Further investigation of YM872 is not planned at this time.
Inhibitors of glutamate release are a heterogeneous group of agents, including anticonvulsants and antidepressants. The proposed mechanism of action for these drugs is ion channel blockade.
The anti-epileptic drug lamotrigine inhibits glutamate release and has shown beneficial effects in a rodent model of focal cerebral ischemia when administered immediately after ischemia 46 ; however, a 2-h delay of treatment produced no effect on infarct volume or neurological outcome in two models. 47 To our knowledge, no clinical stroke trials of lamotrigine have been performed. Similarly, a derivative of lamotrigine, sipatrigine (BW619C89), is a use-dependent sodium channel antagonist that inhibits presynaptic glutamate release. It has been shown to decrease glutamate release during ischemia 48 ; however, like lamotrigine it reduced infarct volume only when administered at onset of ischemia. 49 Sipatrigine has been evaluated in phase 2 clinical trials in patients within 12 h of stroke onset. 50 Like Selfotel, continuous infusion of sipatrigine produced intolerable neuro-psychiatric effects while showing no trend to improved outcomes in a small cohort of 27 patients. A subsequent two-part trial evaluating the maximum tolerated dose and efficacy of sipatrigine was halted early by the trial sponsor and further clinical development of the drug for stroke has ceased. 51 Preclinical studies have shown that phenytoin can reduce neuronal injury, possibly by inhibiting spreading electrical depolarization in penumbral regions and thereby reducing post-ischemic glutamate release. Fosphenytoin, an aqueous-soluble rapidly injectable pro-drug of phenytoin, is another sodium channel blocker. A multicenter combined phase 2/3 evaluation of intravenous fosphenytoin within 4 h of acute stroke was terminated prematurely after interim analysis of 462 enrolled patients showed no difference between placebo and fosphenytoin in any of the functional or disability outcomes. 52 A novel calcium-sensitive maxi-potassium channel opener, BMS-204352, causes neuronal hyperpolarization, decreased calcium influx and glutamate release. 53 A phase 3 trial (POST) of 1978 patients with moderate-to-severe cortical strokes treated within 6 h of onset failed to show any significant beneficial effect when compared to placebo, though these results have not yet been published. A sub-study evaluated the change in lesion volume on MRI over a 12-week period as a biologic surrogate outcome marker. 54 Lubeluzole is a novel benzothiazole compound that has emerged as a neuroprotective agent in animal models of focal ischemia. [55] [56] [57] In some laboratories, lubeluzole has achieved reduction of infarct volume and improved neurologic outcome in animal models even when administered up to 6 h after infarct induction. 55 There are several putative mechanisms by which lubeluzole protects the penumbral region in these models. First, lubeluzole normalizes neuronal activity in the peri-infarct region by inhibiting glutamate release possibly via blockade of non-L-type calcium channels. 58 Additionally, blockade of sodium channels and taurine release by lubeluzole suggests that it may reduce osmoregulatory stress in the peri-infarct zone. Finally, lubeluzole diminishes nitric-oxide-related neurotoxicity. 59 A phase 2 clinical trial of lubeluzole in acute ischemic stroke suggested that lubeluzole lowers mortality and disability in some patients. 60 Two dosing regimens were compared to placebo. Subjects clinically diagnosed with acute ischemic stroke in the middle cerebral artery territory were treated within 6 h of onset of symptoms. The low-dose lubeluzole group experienced no excess of cardiac arrhythmias compared to placebo, although there was a higher incidence of ventricular fibrillation in the high-dose lubeluzole group. Overall mortality was 6% for the lower dose regimen compared to 18% and 35% in the placebo and higher dose regimen of lubeluzole, respectively. The trial was terminated prematurely when a multivariate logistic regression analysis found this significant imbalance in the 28-day mortality favoring treatment with the low-dose regimen. The excess mortality in the higher dose group was partially due to imbalanced randomization with more severe strokes in this group. When multivariate regression accounted for stroke severity, high-dose treatment had no effect on mortality. The BI tended to be higher in the lower dose lubeluzole group, but no significant differences in efficacy measures were found among the groups.
Based on the results of this pilot study, subsequent phase 3 randomized, multicenter, double-blind, placebocontrolled trials adopted the low-dose regimen to test the efficacy of lubeluzole in acute ischemic stroke patients. However, it is essential to note that the low-dose regimen produced a subtherapeutic mean plasma concentration. 61 Three large-scale, multicenter, double-blind, placebocontrolled randomized phase 3 trials of low-dose lubeluzole in stroke patients have produced conflicting results. The European and Australian trial randomized 725 patients within 6 h of onset and demonstrated similar overall mortality, adverse events and clinical outcome between all placebo and lubeluzole-treated patients. 62 However, an unplanned post hoc analysis found that lubeluzole treatment decreased mortality among patients with mild to moderate stroke measured by the Clinical Global Impression rating. The North American trial included 721 patients within 6 h of moderate to severe hemispheric stroke. 63 The mean time to treatment was 4.7 h. The degree of functional recovery (Barthel Index) and disability (mRS) at 3 months significantly favored lubeluzole over placebo after controlling for appropriate covariates. The odds of favorable outcome were 38% higher with lubeluzole according to the global test statistic. This study also found a non-significant improvement in mortality in the lubeluzole group and confirmed the safety of the low-dose regimen with no significant differences in cardiac-related complications or adverse events. Finally, the third efficacy trial randomized 1,786 total patients including a core stroke group consisting of patients with ischemic stroke, excluding patients aged Ͼ75 years with severe strokes, treated within 0 to 6 h. Only the core stroke group was used in the primary efficacy analyses. Lubeluzole had no significant effect on mortality or 12-week functional status in the core stroke group. Similar neutral results were found in the nontarget population including all treated patients. Lubeluzole-treated patients experienced more cardiac events including atrial fibrillation and QT interval prolongation but this was not associated with increased mortality.
Finally, lubeluzole was the first potentially neuroprotective agent to be evaluated in a dedicated combination trial with TPA. Patients who qualified for and received intravenous TPA within 3 h of symptom onset were randomly allocated 1:1 to lubeluzole or placebo. 64 Infusion of medication was started before the end of the 1-h TPA infusion. Eighty-nine patients were enrolled before the early trial termination based on the negative results of the previously described concurrent lubeluzole phase 3 trial. In the enrolled patients (45% of the planned population), TPA and study drug were administered at a mean of 2.5 and 3.2 h from symptom onset, respectively. There were no significant differences in mortality (26%), intracerebral hemorrhage (10%), serious adverse events (51%) or functional outcomes (Barthel Index) between lubeluzole and placebo. These results demonstrate the safety and feasibility of linking ultra-early neuroprotection with thrombolysis, however the premature stoppage of enrollment led to a study underpowered to detect efficacy.
A recent systematic review of five randomized trials, including a total of 3,510 patients, found no evidence that lubeluzole given at any dose reduced the odds of death or dependency at the end of follow-up (odds rated 1.03, 95% CI 0.91-1.19). 65 However, at any given dose, lubeluzole was associated with a significant excess of cardiac conduction disorders. There are several reasons that the lubeluzole trials may have failed to show efficacy. As with many other agents, the time interval from stroke onset to drug administration is most likely too long to meaningfully inhibit glutamate release and action. Although an extended 6-h time window for efficacious treatment has been reported, other animal models have failed to replicate the efficacy of lubeluzole initiated 30 min after ischemia. The discrepant results between the North American and European trials may be in part due to time interval to drug initiation. In the North American trial the mean time interval was 4.7 h. Although a similar mean is not reported by the European trial, over 80% of patients were treated beyond 4 h potentially leading to lessened efficacy. Also, doselimiting side effects, primarily cardiac, led to a narrow therapeutic index with resultant serum levels below the minimum neuroprotective level reported in animals. A preliminary analysis of the pharmacokinetics/dynamics in the European trial found a trend toward improved functional outcome (mRS) in patients with a plasma concentration Ͼ70 ng/ml. Variability in achieved plasma levels may have occurred to account for conflicting reports of efficacy. Although the combination trial of lubeluzole and TPA required treatment within 4 h, its early termination led to underpowered sample size to detect efficacy.
Other neurotransmitter modulators
Serotonin agonists may exert cytoprotection via several actions at pre-and post-synaptic 5-HT 1A receptors, including neuronal membrane hyperpolarization with reduction in glutamate release 66 ; these agents may also inhibit apoptosis. 67 One small trial of 49 acute stroke patients failed to show the efficacy of a serotonin reuptake inhibitor, trazodone, on mortality or neurologic deficit compared to placebo. 68 The neuroprotective efficacy, safety and tolerability of another serotonergic agent are being studied in ongoing acute stroke trials. Repinotan (Bay x 3702) is a serotonin agonist of the 5HT 1A subtype that produces 55% reduction of infarct volume in experimental models of permanent focal ischemia. 69 A phase 2 trial of repinotan identified 1.25 mg/day given for 3 days as a dose that is well tolerated by stroke patients and may improve neurological outcome at 3 months 70 A double-blind, placebo-controlled phase 3 trial is currently randomizing patients with moderate to severe stroke (NIHSS 8-23) to placebo or repinotan within 6 h of symptom onset. Treatment with intravenous thrombolysis is allowed. The drug is administered at a rate of 1.25 mg/day for 72 h and doses are titrated to a targeted blood level of 5 to 20 mcg/l. The primary outcome measure is the Barthel Index at 3 months. Planned enrollment for this phase 3 trial is 600 patients. 71 A safety and efficacy study of a novel neurotransmitter modulator, ONO-2506, is currently recruiting stroke patients within 6 h onset of a radiographically confirmed cortical infarct. The proposed mechanism of action is modulation of glutamate transporter uptake capacity and expression of GABA receptors. 72 The endogenous opioids act at the kappa opioid receptor as excitatory neurotransmitters and potentiators of ischemic injury. Opiate receptor antagonists have exhibited cytoprotective activity in preclinical focal and global models of ischemia. [73] [74] [75] Several small trials of naloxone have failed to conclusively show efficacy in acute ischemic stroke. 76 -80 The equivocal results are likely due to under-powering of these small studies to detect small but significant treatment effects. Also, naloxone is relatively nonspecific for the kappa receptor. Recently, attention has shifted to nalmefene, an opiate antagonist that has relatively pure activity at the kappa receptor.
In a phase 2a trial, nalmefene (0.1 mg/kg) administered within 6 h of stroke onset was found to be tolerable and possibly efficacious. 81 Although no overall treatment effect was observed, a subgroup analysis suggested that nalmefene may confer a beneficial effect in young patients (Ͻ70 years). 82 Based on phase 2 data, a phase 3 trial was designed to study the safety and efficacy of 60 mg of nalmefene administered as a bolus dose followed by continuous infusion over 24 h. 83 A total of 368 patients were randomized within 6 h of stroke onset. This sample size was constructed to detect a 15% improvement with treatment. Concomitant use of TPA was allowed; however, that population was analyzed as a separate subgroup (n ϭ38) and was therefore excluded from the intention-to-treat analysis. There was no significant treatment effect on 3-month outcome on any of the planned analyses, including secondary analyses in young patients and thrombolytic-treated patients. However, the small number of patients within both of these subgroups increases the likelihood of excluding a treatment effect that is actually present. Although the nalmefene-treated patients experienced more nausea, there was not a significant increased incidence of neuro-psychiatric effects.
There are several potential explanations for the negative results of the opioid antagonist trials. As with other upstream modulators of excitotoxicity, delayed treatment may not confer neuroprotection because the pivotal steps in the cascade have already occurred by time of treatment. Also, the trial design did not enforce recruitment of adequate numbers of patient into the subgroups most likely to derive benefit (young patients, moderate-tosevere deficits, thrombolytic-eligible) resulting in an under-powered design. Lastly, no pharmacokinetic studies were performed so the adequacy of dosage is unknown.
Enhancement of GABA-induced inhibition may be a useful target of cytoprotection. Clomethiazole is a GABA agonist that theoretically prevents damage due to excessive excitatory neurotransmitters by enhancing inhibition at the GABA A receptor level. 84 The GABA receptor activation causes increased chloride conductance and membrane hyperpolarization that depresses neuronal depolarization and excitability. 85 Clomethiazole has been shown to exhibit neuroprotection in several focal ischemia models. 86, 87 A dose-escalation trial demonstrated an acceptable safety profile in acute stroke patients with dose-related sedation observed. 88 In this study, 75 mg/kg administered as a continuous infusion over 24 h achieved plasma concentrations comparable to those producing experimental neuroprotection. 89 Therefore this dose was chosen for phase 3 trials.
The Clomethiazole Acute Stroke Study (CLASS) evaluated clomethiazole in a randomized, placebo-controlled manner in hemispheric ischemic stroke patients with a moderate-to-severe deficit within 12 h of onset. 90 The study was powered to detect a 9% difference in the percent of patients reaching relative functional independence with treatment. Efficacy analysis of 1,353 patients revealed a non-significant 1.2% difference favoring clomethiazole in achievement of functional independence assessed by Barthel Index. Sedation was the most common adverse event and led to withdrawal of treatment in 15.6% patients. There was no difference in incidence of cardiopulmonary conditions or progressive stroke between the groups. Onset-to-treatment interval had no effect on recovery between the groups after controlling for age and baseline stroke severity. Subgroup analyses found a significant beneficial effect of clomethiazole in two overlapping groups, those with severe baseline neurological deficit and those classified as having a total anterior circulation stroke. This suggests that patients with the largest strokes may have a larger penumbra that may be salvaged by cytoprotective therapy. 91 The Clomethiazole Acute Stroke Study in Ischemic Stroke (CLASS-I) was designed to test the hypothesis generated by the previous CLASS trial: clomethiazole is effective in patients with large ischemic anterior circulation strokes. 92 Ischemic stroke patients with evidence of higher cortical dysfunction plus visual field and motor deficit were randomized within 12 h of onset to placebo or clomethiazole. The mean NIHSS score was 16.9 and the mean time to treatment was 7.7 h. The population kinetic assay produced a therapeutic plasma concentration during the 24-h infusion. There was no evidence of efficacy on any of the outcome variables including NIHSS score, BI, mRS, and 30-day lesion volume.
The absence of treatment effect occurred despite adequate trial design based on sound preclinical data, appropriate patient selection, and adequate drug concentrations. Once again, the lack of efficacy may be based on the prolonged time window of 6 h or the inadequate prediction of human pharmacokinetics based on rodent data.
A large international trial is recruiting patients to study the effect of diazepam, a benzodiazepine with established GABA-ergic activity, within 12 h of stroke onset. There are no preliminary results thus far. 93 In summary, a large number of drugs that target glutamate and other neurotransmitter function have shown preclinical efficacy but have failed in clinical trials. A major factor has been side effects that limit dose, but even those that have achieved therapeutic dose ranges and have been sufficiently powered (GAIN and CLASS) have been neutral or negative. Currently, the best remaining hope for this strategy is with ongoing trials of magnesium. However, taken in their entirety, the data suggest that monotherapy targeting a single neurotransmitter function may not provide sufficient neuroprotection to provide clinically meaningful benefit.
Free radical scavengers, adhesion molecule blockers, steroids, and other anti-inflammatory strategies
Other strategies of neuroprotection attack later stages of the ischemic cascade. Nitric oxide (NO) synthesis is induced by stimulation of glutamate receptors, and NO in turn has a number of complex actions relevant to ischemia and cell injury. Endothelium-derived NO causes vasodilatation beneficial to ischemic brain, but neuronal NO generates oxygen free radicals toxic to cells. In animal models of stroke, NO synthase inhibitors have complex effects befitting the dual role of NO in cerebral ischemia. The usefulness of NO modulation in stroke likely will hinge on the ability to favorably manipulate the beneficial and deleterious effects of NO.
Reactive oxygen intermediates play a role in ischemic tissue damage and represent another later target for cytoprotection. Tirilazad mesylate is a 21-aminosteroid free radical scavenger and potent membrane lipid peroxidation inhibitor that has shown neuroprotective promise in focal ischemia and subarachnoid hemorrhage models. 94, 95 This agent protects the microvascular endothelium and maintains intact BBB and cerebral autoregulatory mechanisms. Unfortunately, this agent has limited penetration into the brain parenchyma and may lead to unsatisfactory efficacy in stroke, as demonstrated by clinical trials to date. 96 A sequential dose-escalation trial determined that tirilazad doses of up to 6 mg/kg/day for 3 days are safe and well tolerated when administered within 6 h of acute stroke. 97 A phase 3 randomized trial of tirilazad within 6 h of stroke onset was terminated prematurely after a pre-planned interim analysis of 660 patients determined futility of continued enrollment. 98 No statistically signif-icant difference was found in the proportion of patients achieving a favorable outcome due to tirilazad treatment administered at a median of 4.3 h. The lack of efficacy in this trial was in part ascribed to inadequate dosing, especially in women, and a second tirilazad trial was designed using a higher dosing regimen. 99 This trial was discontinued prematurely for safety concerns raised by a concurrent European trial, despite trends toward reduced mortality and dependence in both men and women. A recent systematic review of six randomized, controlled trials (Ͼ1,700 patients) included previously unpublished data from two large negative European trials. 100 This review found that tirilazad actually increases death and disability by one-fifth. Additionally, subgroup analyses demonstrated a significantly worse outcome in women and patients treated with lower doses of tirilazad, as well as trends for worse outcome in patients with mild to moderate stroke.
A sub-study of the European trials determined that early tirilazad treatment (Ͻ6 h) had no significant effect on infarct volume in the whole population. However, post hoc analysis found that men with cortical infarcts have a significant reduction in infarct volume; this beneficial effect was no longer significant after adjustment for age and stroke severity. 101 It is still unclear if tirilazad exhibits not only a lack of neuroprotection but may induce worsening within specific populations of patients. Potential reasons for these results include controversial results of preclinical studies, 102 delayed drug administration (more than 75% patients treated after 3 h), thrombophlebitis causing a systemic inflammatory state and inadequate BBB permeability. Finally it is possible that generation of free radicals plays a positive role in the recovery of stroke patients.
Ebselen is another type (seleno-organic) of antioxidant that potentially inhibits lipid peroxidation through multiple mechanisms. These include inhibition of lipoxygenase within the arachidonate cascade, blocked production of superoxide anions by activated leukocytes, 103 inhibition of inducible NO synthase, 104 and glutathione-like inhibition of membrane lipid peroxidation. 105 An unpublished phase 2b dose-escalation trial determined 300 mg/ day to be the optimal dose. A single randomized efficacy trial has shown that early treatment with ebselen improved outcome after acute ischemic stroke. 106 In this trial, ebselen was administered orally to patients within 48 h of ischemic stroke onset. There was no statistically significant difference in mortality. Intention-to-treat analysis demonstrated that ebselen treatment achieved a significantly better outcome at 1 month, but only a trend to improvement was observed at 3 months. Although the ebselen group included slightly more patients with mild impairment than the placebo group, the difference was not significant and the efficacy of ebselen was also demonstrated in patients with moderate-to-severe deficits.
Ebselen treatment within 24 h significantly improved the likelihood of good recovery on the Glasgow Outcome Score compared to placebo (42% versus 22%, p ϭ 0.038), whereas treatment after 24 h led to no significant differences between the groups. Based on the results of this adequately powered trial, ebselen is felt to be safe and possibly efficacious.
Currently, a multicenter phase 3 ebselen trial is recruiting patients. This trial will determine the efficacy of ebselen in patients with clinical and radiographic cortical stroke within 24 h of symptom onset. Planned enrollment is 390 patients and primary outcome is Glasgow Outcome Score at 3 months.
Free radical production occurs during ischemia and reperfusion and contributes to the neuronal injury after stroke. Several nitrone free radical trapping agents (spintrap agents) have demonstrated neuroprotection in both transient and permanent focal ischemia rodent models. 107, 108 NXY-059 (disodium 4-[(tert-butylimino) methyl] benzene-1,3-disulfonate N-oxide) is a novel nitrone-based compound that has free radical trapping properties. The neuroprotective efficacy of NXY-059 is retained even when given up to 5 h after onset of ischemia. In a primate model of permanent focal ischemia, NXY-059 significantly decreased neurological disability and reduced infarct volume in both cortical and subcortical regions. 109 Pharmacokinetic studies reveal that NXY-059 produces dose-dependent neuroprotection at unbound plasma concentrations of 50-150 mol/l.
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A randomized, double-blind, placebo-controlled phase 2 trial evaluated the tolerability and pharmacokinetics of two NXY-059 dose regimens in stroke patients. 111 Patients were randomized within 24 h of stroke onset to placebo, low-dose or high-dose NXY-059. Treatment was administered as a loading dose over 1 h followed by a continuous infusion over 71 h. The infusion rate was reduced by 50% in patients with impaired renal function (calculated creatinine clearance 50 to 59 ml/min). These dose regimens were designed to reach a target unbound plasma concentration Ͼ40 mol/l that has demonstrated neuroprotection in rodents. One hundred fifty patients were enrolled at a mean of 15 h after symptom onset. No increase in overall incidence of adverse events occurred in the NXY-059 group compared to placebo. However, more severe adverse events and deaths occurred within the low-dose NXY-059 in accordance with the increased number of primary intracerebral hemorrhages within this group. Common adverse events included hyperglycemia, headache, and fever, but were not related to treatment. The mean unbound plasma concentrations were 25 and 45 mol/l in the low-and high-dose groups respectively. Similar to other phase 2 studies, these concentrations were well tolerated and below the target level. Therefore, study of higher NXY-059 doses was justified. A phase 2b/3 study is planned to determine the efficacy of a higher dose regimen (2,264 mg loading dose, up to 947 mg/hr infusion over 71 h). Planned enrollment is 1,550 acute stroke patients within 6 h of stroke onset with concurrent use of intravenous thrombolytics allowed. Primary outcome measure is mRS score.
Complex inflammatory processes mediate ischemicand reperfusion-related brain injury and these represent an ideal downstream target for cytoprotection. Modulation of cytokines, inflammatory-related enzymes (NO synthase), endothelial leukocyte interactions, leukocyte activation, and gene transcription factors has been investigated in experimental models and a few clinical trials.
Various models of focal ischemia have demonstrated increased expression of leukocyte-endothelial adhesion molecules, 112, 113 and the absence of adhesion molecules in knock-out mice significantly reduces infarct size. 114, 115 Anti-adhesion molecule strategies have shown efficacy only in models of transient ischemia supporting the belief that neuroprotection will impart significant benefit only when coupled to reperfusion. 116, 117 Furthermore, animal studies have demonstrated that combination therapy of TPA and anti-adhesion therapy (either anti-ICAM-1 or anti-CD-18 antibody) significantly reduces infarct volume and neurologic deficit score more than either agent alone even when administered up to 4 h after ischemia induction. 118 Although contradictory evidence for up-regulation of inflammatory adhesion molecules in ischemic stroke patients exists, the majority of studies demonstrate elevations in circulating adhesion molecules (soluble (s)I-CAM-1, sVCAM-1, sP-selectin, and sE-selectin). 119 -121 Elevated ICAM-1 expression has been observed on microvessels within infarcts in patients surviving 15 h to 6 days post-stroke. 122 Enlimomab is a murine monoclonal anti-ICAM-1 antibody that has undergone phase 3 testing in stroke patients. A preliminary open-label pilot dose-ranging study identified a dose that was generally well tolerated and produced the target serum level thought to be neuroprotective. 123 A subsequent phase 3 trial tested the efficacy of this dosing regimen (160 mg on day 1 followed by a maintenance dose of 40 mg/day for 4 days) compared to placebo in 625 ischemic stroke patients within 6 h of symptom onset. 124 This dose achieved the target level in 96.6% of patients after the first dose, and adequate trough levels were maintained throughout the duration of treatment. Enlimomab treatment was associated with worse disability and increased mortality compared to placebo. The hazard of death averaged over the first 90 days was 43% higher in enlimomab-treated patients than placebo-treated patients. Adverse events reported more frequently by the active treatment group included fever, myocardial infarction, pulmonary edema, pneumonia, stroke progression, cardiac arrest, meningitis, cerebral edema, and intracerebral hemorrhage. Fever was reported twice as often in enlimomab-treated patients. However, the negative effect of treatment cannot be ascribed solely to the drug's propensity to cause fever since stroke outcome was marginally improved in febrile patients on enlimomab compared to placebo, whereas afebrile patients on enlimomab had a worse outcome.
There are several possible explanations for the negative effect of enlimomab. First, enlimomab is a different type of antibody than that used in experimental models. It is possible that murine anti-ICAM antibody led to up-regulation of endogenous adhesion molecules and precipitated a paradoxical inflammatory response. It has been shown that all enlimomab-treated patients develop anti-mouse antibodies. An experimental model was subsequently designed to mimic the negative clinical trial. Administration of this murine antibody to rats leads to production of host humoral response against the protein, activation of compliment, neutrophils, and microvascular system. 125 Second, no preclinical model delayed treatment for 6 h or administered the drug for 5 consecutive days as in the clinical trial. Most importantly, animal studies showed no treatment benefit in permanent ischemia models. Only a minority of patients (4% to 24%) have spontaneous reperfusion, and hence most enrolled patients were not comparable to transient ischemia models that were associated with treatment benefit. Therefore, the rational approach to future immuno-modulatory therapies would be development of humanized anti-adhesion molecule strategy with a revised (shorter) dosing regimen and coupling to thrombolysis.
To this end, a humanized IgG1 antibody against human CD18 (Hu23F2G or LeukArrest) was developed to block leukocyte infiltration while avoiding the complications of enlimomab due to sensitization. Phase 1 and 2 data revealed no safety concerns associated with LeukArrest. A phase 3 trial enrolled patients within 12 h of stroke onset, allowed concomitant TPA use, and employed a reduced frequency of dosing schema. The phase 3 trial of Hu23F2G was terminated after interim futility analysis determined that treatment was unlikely to impart significant benefit if the trial was continued. To date, the data from this trial remain unpublished.
Promising new strategies are developing to target other "downstream" events of the ischemic/excitotoxic cascade, the calcium-dependent enzymatic reactions mediating necrotic and apoptotic cell death. Theoretically, since these processes occur "later" in the cascade, the therapeutic time-window may be prolonged. Several important enzymes have been characterized as potential targets of neuroprotection. 126, 127 Inhibition of these enzymes may be effective in preserving the structural integrity of neurons. Multiple experimental models have demonstrated the efficacy of calpain, caspase, and protein kinase inhibitors in reducing infarct volume up to 6 h after onset of ischemia.
128 - 131 The inability of these large protein compounds to cross the BBB has thus far limited clinical development. However novel strategies are developing to enhance delivery of neurotherapeutics to the brain. Recently minocycline has demonstrated protective effects in hypoxic-ischemic, focal, and global ischemia models. 132, 133 Minocycline, a semi-synthetic secondgeneration drug of the tetracycline group, is a safe and readily available compound that exerts anti-inflammatory effects such as inhibition of microglial activation and production of other inflammation mediators. Furthermore, minocycline may inhibit the activity of matrix metalloproteinases (MMP), diminish permeability of the BBB, inhibit caspase, inducible NO synthase (iNOS) and p38 mitogen-activated protein kinase (MAPK). 134 The neuroprotective efficacy of minocycline has been demonstrated in animal models even when delayed up to 4 h. Minocycline appears to be an ideal neuroprotective candidate based on its established safety profile, good CNS penetration, wide availability, and inexpensive cost, and therefore deserves evaluation in clinical trials of acute ischemic stroke.
FK506 (Tacrolimus) has been widely used for prevention of transplant organ rejection, and is now being investigated as a potential neuroprotectant based on its immunosuppressive properties. FK506 suppresses the calcium-dependent signal transduction pathway that promotes proliferation of helper T cells by inhibition of calcineurin. 135 Apoptotic cell death is also attenuated by FK506. 136 Multiple animal models demonstrate the neuroprotective effects of FK506 by reduced infarct volume both histologically and radiographically. [137] [138] [139] [140] [141] A new formulation of FK506 has been developed for the acute stroke indication, FK506 Lipid Complex-Gilead (FK506 LCG). Preliminary studies demonstrated a dose-dependent hypothermia and increase in blood pressure in animals, and a transient increase in blood pressure and heart rate in humans. Overall, this compound was well tolerated and a randomized, double-blind, placebo-controlled dose-escalation study is planned to determine the safety, tolerability, and pharmacokinetics of FK506 LCG in stroke patients. Criteria for enrollment include ischemic stroke within 12 h of onset, and moderate-to-severe deficit with clinical evidence of cortical involvement.
Corticosteroids theoretically may interrupt the inflammatory cascade that occurs during stroke. Recent experimental data posits that corticosteroids activate endothelial NO synthase activity via a non-transcriptional pathway, thereby augmenting regional cerebral blood flow and reducing infarct volume. 142 Although corticosteroids substantially reduce stroke size in experimental models, trials using various routes of administration, dosage, and duration of treatment with dexamethasone have failed to demonstrate a beneficial effect of steroids. 143, 144 Steroids do, however, increase infectious and hyperglycemic complication rates. A systematic review of published randomized trials comparing steroids to placebo within 48 h of onset concluded that there is insufficient evidence to justify corticosteroid use after ischemic stroke. 145 In this review, data from 453 patients within seven trials revealed that treatment did not reduce mortality or improve outcome. The substantial time delay to drug administration is a possible culprit for negative results. Additionally, the detrimental side effects of corticosteroid may be mediated by the transcriptional genomic activities of steroids, thereby limiting their clinical utility. Therefore, novel compounds that selectively activate non-transcriptional glucocorticoid receptor activity may provide neuroprotection without the deleterious effects. 146 Such compounds are under development. Human serum albumin is a multifunctional protein with neuroprotective properties in experimental models of focal ischemia even when administered up to 4 h after induction of reversible ischemia. 147 Several mechanisms have been speculated for its neuroprotective capacity, including inhibition of lipid peroxidation (antioxidant), maintenance of microvascular integrity, inhibition of endothelial cell apoptosis, 148 hemodilution, and mobilization of free fatty acids required for restoration of damaged neurons. 149 Although non-albumin hemodilution trials have failed to demonstrate benefit, these were designed to test efficacy of hemodilution, not cytoprotection per se. A pilot study of albumin is underway.
Membrane "stabilizers" and trophic factors
The monosialoganglioside GM-1 is thought to limit excitotoxicity and facilitate nerve repair and regrowth. In a study of 792 acute stroke patients, there was a nonsignificant trend toward greater recovery in patients treated for 3 weeks with GM-1 compared to placebo. 150 Post hoc analysis showed a statistically significant difference in neurologic outcome favoring GM-1 in the subgroup of patients treated within 4 h. There was no difference in mortality, and the drug had no significant side effects. To our knowledge, no further studies of gangliosides in acute stroke are planned.
Cerebrolysin is a compound consisting of free amino acids and biologically active small peptides that are products of the enzymatic breakdown of lipid free brain products. Experimental models have demonstrated neuroprotection although the mechanism of action is unclear. 151 Several European small trials have suggested that cerebrolysin administered as a continuous infusion for 20 days improves motor function and global function compared to placebo. 152 Larger clinical trials would be required to confirm neuroprotection and determine pharmacokinetics/dynamics of this peptide.
Energy failure and activation of phospholipases during ischemia lead to breakdown of cellular membranes and ultimately to neuronal death. Cytidine-5Ј-diphosphocho-line (citicoline) is the rate-limiting intermediate in the biosynthesis of phosphatidylcholine that is incorporated into the membrane of injured neurons and may prevent membrane breakdown into free-radical-generating lipid byproducts. Citicoline has exhibited a neuroprotective effect in a variety of CNS injury models, including focal ischemia. 153 However, the neuroprotective capacity is modest, and is lost if the onset of treatment is delayed by 3 h. 154 Despite the extensive work performed with experimental models, the exact mechanism of action remains elusive. However, it is believed to be due to increased phosphatidylcholine synthesis and inhibition of phospholipase A2 within the injured brain. During ischemia, choline supply is limited and membrane phospholipids are hydrolyzed to provide a source of choline for neurotransmitter synthesis. This autocannibalism ultimately leads to death of cholinergic neurons. Additionally, recent evidence shows that citicoline reduces expression of pro-caspases and other proteins involved in apoptotic cell death after focal ischemia. 155 A randomized dose-response trial in 259 patients found a significant difference in functional outcome (BI and mRS), neurologic function (NIHSS score), and cognitive function (MMSE) favoring oral citicoline. 156 Both 500 and 2000 mg citicoline had a significant effect on favorable outcome at 3-month outcome (BI) after adjustment for initial stroke severity. There were no doserelated serious adverse events or deaths with the exception of mild dizziness experienced at 2000 mg/day. A subsequent phase 3 U.S. trial randomized 394 acute ischemic stroke patients within 24 h of onset to placebo or citicoline (500 mg orally daily) for 6 weeks. Patients with moderate-to-severe strokes within the middle cerebral artery territory were included. 157 An imbalance of stroke severity occurred with significantly more patients with NIHSS Ͻ8 randomized to the placebo group. There was no statistical difference in planned secondary analyses and the primary efficacy analysis was rendered unreliable due to non-proportional distribution of patients. Post hoc analyses revealed that in the subgroup of patients with baseline NIHSS Ͼ7, citicoline-treated patients were significantly more likely to achieve a full recovery (placebo 21%, citicoline 33%, p ϭ 0.05).
Based in part on this subgroup analysis, another large phase 3 trial was conducted to evaluate the efficacy of higher dose citicoline (2000 mg/day) administered within 24 h of onset to patients with baseline NIHSS Ͼ7.
158 There was no difference between citicoline and placebo-treated patients in the planned primary outcome defined as improvement from baseline NIHSS score Ն7 points. However, post hoc analyses found a significant positive effect of treatment on recovery and a global test of multiple outcomes. The neutral results of this trial may have been due to the chosen primary endpoint that may not be reflective of recovery.
An important trial evaluating the effect of citicoline on MRI lesion volume demonstrated the potential utility of neuroimaging as a surrogate marker of neuroprotective efficacy. 159 One hundred patients with baseline NIHSS score Ͼ4 presenting with a diffusion-weighted abnormality within 24 h of stroke onset were randomized to placebo or citicoline 500 mg/day for 6 weeks. At 12 weeks, the ischemic lesion volume expanded by 180% in placebo patients compared with 34% among citicolinetreated patients. A significant association was found between reduction of lesion volume and improvement of NIHSS by 7 points or more. This relationship between clinical outcome and lesion volume supports the use of diffusion-weighted image as a surrogate marker of neuroprotective efficacy.
Finally, intravenous citicoline of various doses and treatment duration has been evaluated in several non-U.S. trials with significant improvements in recovery demonstrated by all trials. A small pilot study comparing the efficacy of citicoline (1,000 mg/day for 30 days) to placebo found that 71% of citicoline-treated patients improved from baseline compared with only 31% of placebo-treated patients. 160 The largest trial included 272 patients randomized to citicoline or placebo. In this trial a 26% relative difference on a global improvement rating scale favoring citicoline treatment over placebo was demonstrated. 161 A recent meta-analysis of 7 controlled clinical stroke trials showed that citicoline treatment was associated with significant reductions in rates of long-term death or disability. 162 A more recent pooled analysis of oral citicoline clinical trials in acute ischemic stroke sought to determine the effects of citicoline on neurologic recovery. 163 A systematic search identified all prospective, randomized, placebo-controlled, double-blind clinical trials of citicoline in patients with moderate-to-severe strokes (NIHSS score Ն8) and good pre-stroke functioning (mRS Ͻ2). Of 1,652 total patients, 1,372 fulfilled the inclusion criteria. Three-month recovery (composite NIHSS Յ1, mRS Յ1, BI Ն95) was achieved in 25.2% citicoline-treated patients compared with 20.2% placebotreated patients (Table 6 ). The largest difference in recovery was seen in patients treated with the highest dose (2000 mg) of citicoline. The promising results of these large-scale analyses will likely prompt further citicoline studies since this is the first time that meta-analysis of cytoprotective trials has yielded positive results.
Finally, combination of citicoline and intravenous thrombolysis has been shown to significantly reduce infarct volume compared with either treatment alone in a rat embolic stroke model; however, this treatment combination has not yet been tested in humans. 164 Given the positive results of the recent meta-analyses, evaluation of combined citicoline and TPA appears to be the logical next step.
Erythropoietin (EPO) is a mediator of the physiological response to hypoxia via activation of the EPO receptor, a member of the cytokine-receptor superfamily. The overall result of EPO receptor activation is cell proliferation, inhibition of apoptosis, and erythroblast differentiation. 165 EPO may also provide antioxidant activity and resistance to glutamate toxicity. 166 -168 A focal ischemia model demonstrated that intraperitoneal epoetin alpha administered 6 h after ischemia provided 50% protection and this protection occurs via an anti-apoptotic mechanism. 169 An initial safety study revealed that intravenously administered EPO is safe and able to enter the brain in stroke patients. Currently a clinical trial is underway to test the efficacy of recombinant human EPO in acute stroke.
Trophic factors are emerging as potential cytoprotective agents, although their role may be more important in the recovery phase. Basic fibroblast growth factor (bFGF, Fiblast) is a polypeptide that is trophic for brain neurons, glia, and endothelial cells and may prevent down-regulation of anti-apoptotic proteins such as Bcl-2. 170 Animal studies have shown that bFGF is effective in reducing infarct volume in acute ischemia models, as well as promoting synaptogenesis and functional recovery. 171, 172 Additionally, synergistic protective effects have been observed with the combination of bFGF with either citicoline or caspase inhibitors. 173, 174 A double-blind, placebo-controlled clinical trial evaluated two doses of bFGF (5 mg or 10 mg) compared to placebo. 175 Patients with acute, moderate-to-severe stroke (NIHSS Ͼ6) were randomized within 6 h of onset to a single 24-h infusion of bFGF or placebo. An interim efficacy analysis predicted only a nominal chance of significant benefit and the trial was terminated after enrolling 286 of 900 planned patients. A non-significant trend for favorable outcome was seen in the low-dose group, whereas a non-significant disadvantage was seen in the high-dose group. Post hoc analysis further suggested efficacy of the low-dose regimen. Dose-dependent adverse events included leukocytosis and relative hypotension. An unpublished, multicenter controlled phase 2/3 trial was halted after interim analysis revealed significant increased mortality in patients treated with bFGF.
The poor BBB penetration of bFGF necessitated high systemic doses and peripheral side effects may offset the therapeutic effect. Recently, conjugation of bFGF to a BBB drug-delivery vector (OX26-SA) has demonstrated neuroprotection at a lower, systemically administered dosage in a rodent model. 176 Other trophic factors such as platelet-derived growth factor, insulin-derived growth factor, and glial cell linederived neurotrophic factor have also shown promise in animal stroke models, possibly through angiogenic mechanisms. [177] [178] [179] These have not been studied in humans. Many of the novel neuroprotectants, especially trophic factors and anti-inflammatory agents, exist as peptides unable to cross the BBB. Animal models have demonstrated enhanced delivery and neuroprotection when protein agents are conjugated to a delivery vector. Such enhanced delivery mechanisms include reformulation of the neurotherapeutic protein by conjugation and biotinylation, or creation of a fusion protein linked to transduction domains. Enhanced drug delivery systems have several benefits. First, obviously this may enable delivery of neurotherapeutic agents that otherwise do not have access to the brain. Secondly, neuroprotection may be achieved at lower systemic doses thereby allowing administration of agents previously exhibiting dose-limiting side effects. Lastly, conjugation to BBB delivery vectors may decrease distribution to peripheral organs. Experimental models have already demonstrated these benefits. Bcl-XL, an anti-apoptotic peptide member of the Bcl-2 protooncogene family, was successfully fused to the HIV TAT protein, penetrated the BBB after systemic administration and imparted neuroprotection.
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Hypothermia
The neuroprotective action of mild-to-moderate (29°C to 35°C) systemic hypothermia has been demonstrated in numerous animal models of global and focal cerebral ischemia. [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] There are many hypothesized mechanisms for this protection, including restoration of neurotransmitter balance, 191, 192 reduction in cerebral metabolism, 193 preservation of the BBB, inhibition of apoptosis, 194 and attenuation of inflammatory response. 195, 196 Perhaps the consistent and robust benefit of hypothermia across multiple laboratories and animal models is because it works through multiple pathways, all conspiring to have a greater effect than more precisely targeted therapies. Several general principles have emerged from the extensive work investigating the cerebro-protective effects of hypothermia.
First, hypothermia applied during the ischemic period (intra-ischemic) is more protective than hypothermia after reperfusion (post-ischemic). The efficacy of postischemic hypothermia is dependent upon the interval between onset of ischemia and induction of hypothermia, achievement of target temperature, and duration of treatment. Lastly, hypothermia is more efficacious for global ischemia/reperfusion than for focal ischemia, and for transient focal ischemia than for permanent focal ischemia, suggesting that hypothermia may be most beneficial when coupled to thrombolysis/recanalization.
Hypothermia after cardiac arrest has been investigated with use of surface cooling techniques. 197, 198 Recently, two large trials have been published conclusively establishing the neuroprotective effects and safety of hypothermia after cardiac arrest. 199, 200 These studies are the first proof of principle that neuroprotection can be realized in humans. The median time to achieve target temperature from return of spontaneous circulation was 8 h with surface cooling (FIG. 4) . Neurologic outcome was significantly improved in patients treated with hypothermia compared with controls in both trials (Table 7 and  Table 8 ). The efficacy demonstrated, despite relatively long delay times to achieving target temperature, is consistent with animal studies after global forebrain isch- Observations have been made that hyperthermia independently predicts poor outcome in stroke patients, whereas lower body temperature at presentation is associated with improved survival and clinical outcome. [202] [203] [204] [205] Several studies have also looked at the safety and feasibility of hypothermia in ischemic stroke patients. 206 -211 However, the majority of these studies have focused on salvage hypothermic management of elevated intracranial pressure in patients with malignant middle cerebral artery territory infarcts, rather than as a standalone neuroprotective modality. These early studies have used surface cooling methods to achieve significant depths of hypothermia requiring sedation/neuromuscular blockade for patient tolerance of cooling.
In a pilot study, Kreiger et al 210 used surface cooling to achieve post-ischemic hypothermia to 32°C in 10 ventilated and sedated patients. All patients had severe middle cerebral artery (MCA) infarcts, and the majority were treated with either intravenous or intra-arterial TPA before hypothermia. Hypothermia was initiated 6.2 Ϯ 1.3 h after stroke onset, with achievement of maximal hypothermia at 3.5 Ϯ 1.5 h after initiation of cooling. The duration of hypothermia (mean 22.8 Ϯ 8 h) was determined by reestablishment of cerebral perfusion as determined by serial transcranial Doppler examinations. This study showed that post-ischemic hypothermia is safe and feasible after administration of TPA in stroke patients.
Kammersgaard et al 207 published a case-control study illustrating the feasibility of moderate hypothermia in awake patients within 12 h of stroke onset. Hypothermia was initiated upon admission with surface cooling to achieve 35.5°C and was maintained for 6 h. Pethidine (meperidine) was effectively used to reduce shivering in all patients. This data supports the feasibility of using mild hypothermia to treat awake stroke patients without the inherent risks of intubation, sedation, and paralytics.
Translating the neuroprotection established with early hypothermia in preclinical intra-ischemic and early postischemic models to human stroke patients has been one of the most difficult obstacles thus far. Hypothermia must be rapidly initiated and stably maintained. Endovascular cooling via specialized intravenous catheters may be a more efficient means of inducing and maintaining hypothermia, and possibly enhancing the efficacy of neuroprotection. Georgiadis et al 211 evaluated the feasibility and safety of catheter-induced cooling in acute stroke patients. The rate of cooling was 1.4 Ϯ 0.6°C/h, which is faster than the majority of surface cooling techniques. Two of the patients in this study were treated with i.v. TPA; however, the delay between TPA and catheter insertion/hypothermia induction did not permit adequate evaluation of safety.
Ongoing safety and feasibility trials are being conducted with catheter-induced hypothermia in both cardiac arrest and stroke patients. One current trial is investigating 12 and 24 h of catheter-induced hypothermia (33°C) within 12 h of stroke onset in awake patients, some treated with i.v. TPA. This current work is being performed in awake patients using pharmacologic reduction of the shivering threshold with buspirone and meperidine. Such shivering protocols obviate the need to intubate, sedate, and paralyze patients, which prevents adequate monitoring of neurologic status and predisposes to infectious and cardiovascular adverse events.
Caffeinol
A novel combination of the combination of caffeine and ethanol (caffeinol) has demonstrated more robust neuroprotection than many other experimental and clinically relevant agents tested in the laboratory. 212 When used individually, caffeine had no effect and ethanol actually increased infarct volume. However, animal studies have demonstrated a significant 83% reduction in infarct volume with the acute administration of the combination of caffeine 10 mg/kg and 5% ethanol 0.325 gm/kg given intravenously over 120 min in rats subjected to experimental focal cerebral ischemia. Significant benefit was seen with treatment delayed up to 3 h post-stroke. Extensive work has shown that combining i.v. TPA with caffeinol imparts no increased risk of intracranial hemorrhage in vivo, and no reduction of TPA fibrinolytic activity in vitro. 213 The protective effect of caffeinol has recently been confirmed in the suture model of transient MCA occlusion, with the predominant effect on cortical salvage. The protective mechanism is likely due to the synergistic effect of caffeine and ethanol on the excitatory/inhibitory balance between neurotransmitter systems. Adenosine and NMDA receptor antagonism and GABA enhancement are hypothesized to be mechanistically involved in this neurochemical.
An open-label, dose-escalation evaluation of caffeine and ethanol in acute ischemic stroke patients within 6 h of symptom onset has been completed. 214 Twenty-three patients with suspected cortical infarct with NIHSS score Ͼ4 were treated at doses ranging from 6 to 8 mg/kg of caffeine and 0.2 to 0.4 gm/kg of ethanol over 2 h to determine the optimal dose. Concomitant thrombolytic therapy was given in 8 patients. A dose has been identified that results in plasma levels that produce optimal therapeutic effect in animals (caffeine 5 to 10 g/ml and ethanol 30 to 50 mg/dl) and that are clinically well-tolerated by patients without any significant adverse effects.
Combining caffeinol with hypothermia to 35°C increased the amount of neuroprotection in a focal ischemia model compared to either caffeinol or hypothermia alone. 213 In this model, hypothermia was started 60 min after the onset of ischemia and continued for 240 min. A pilot study designed to establish the feasibility and safety of administering both caffeinol and mild systemic hypothermia in acute ischemic stroke patients treated with i.v. TPA, within 5 h of symptom onset (caffeinol within 4 h and hypothermia within 5 h) is just starting. The dosing schedule (8 mg/kg and 0.4 gm/kg 10% ethanol) identified in the caffeinol dose-escalation trial will serve as the template.
Blood substitutes and oxygen delivery
Compounds derived from human hemoglobin have a dual property: they may be neuroprotective by improving tissue oxygenation, and they may also augment perfusion because of their low viscosity. Several cell-free hemoglobin solutions are under clinical evaluation, but development has been cautious because of concerns about potential allergic and infectious complications, and nephrotoxicity. The agent that went farthest along in clinical development is diaspirin cross-linked hemoglobin (DCLHb), which is human hemoglobin derived from banked red blood cells, heat-treated, and diaspirin crosslinked to prevent dissociation. It has similar oxygen affinity to that of blood. Probably because hemoglobin binds endothelial NO, it has a slight pressor effect. Studies in animal stroke models have consistently shown improved perfusion of ischemic regions and reduced infarct size. [215] [216] [217] [218] In one study, DCLHb was able to double the length of time MCA occlusion could be withstood before ischemic damage appeared. 218 A multicenter, single-blind phase 2 safety/dose-finding trial randomized 85 patients to DCLHb or saline. 219 Patients with acute ischemic stroke in the anterior circulation, within 18 h of onset of symptoms were enrolled. Three DCLHb dosing regimens were evaluated, each involving 12 doses over 72 h. DCLHb caused a rapid rise in mean arterial blood pressure. The pressor effect was not accompanied by complications or excessive need for antihypertensive treatment. Multivariate logistic regression analysis showed that a severe stroke at baseline and treatment with DCLHb were independent predictors of worse outcome (mRS 3-6) at 3 months. More serious adverse events and deaths occurred in DCLHb-treated patients than in control patients.
Normobaric hyperoxia confers cortical protection when administered within 30 min of ischemia in rodents. 220 Normobaric therapy is practically easier to deliver than hyperbaric therapy. Based on its simplicity, low cost and safety, normobaric hyperoxia may be initiated by first responders in the field and clinical trials are anticipated.
Hyperbaric oxygen (HBO) treatment presumably increases oxygen delivery to the ischemic penumbra, thereby prolonging the functional activity of this potentially salvageable tissue. Mechanistically, administration of 100% oxygen at greater than atmospheric ambient pressure increases the amount of oxygen physically dissolved in blood. Other postulated protective actions include inhibition of neutrophil sequestration 221 and reduction of peri-infarct glucose, glutamate, and pyruvate levels. 222 Although the majority of animal models demonstrate a beneficial effect of HBO on outcome and infarct volume, [223] [224] [225] [226] [227] others do not, 228 -230 and controversy prevails regarding the neuroprotective potential of HBO therapy in both clinical and experimental focal ischemia. Increased free radical generation and lipid peroxidation is a theoretical risk of HBO that may counteract neuroprotective mechanisms of action. A study of HBO at three atmospheres in a rodent model of focal ischemia demonstrated neuroprotection without alteration of lipid peroxidation.
Human experience with ischemic stroke and HBO treatment yields similar conflicting results. 231, 232 A double-blind pilot study evaluated the safety and efficacy of HBO ther-apy compared to hyperbaric air (HBA) in patients within 24 h of ischemic stroke onset. A total of 34 patients were exposed to 40 min of hyperbaric treatment (17 HBO, 17 HBA) at 1.5 atmospheres for 10 dives total. The mean Orgogozo neurological assessment score at 1 year was significantly better with the HBO therapy than HBA; however, no statistical difference was found in the mRS scores or net difference between pre-and post-treatment scores. This study concluded that HBO treatment was safe and possibly efficacious. A larger trial is recruiting patients.
Conclusion
In summary, encouraging signals have recently been detected in human studies of hypothermia after cardiac arrest and citicoline for ischemic stroke, suggesting that clinically meaningful cytoprotection after stroke may still be achievable despite 10 years of largely failed trials. An ongoing large trial of magnesium is nearing completion. If this trial is negative, it should determine once and for all that delayed treatment with drugs targeting single "upstream" events will not succeed. Phase 1 and 2 trials that are now being designed reflect the lessons learned from earlier failed trials. These include ultra-early treatment (FAST-MAG), targeting "downstream" events (FK506, NXY-059, trophic factors, EPO, albumin) that may be more amenable to post-ischemic treatment, or combining agents that together have high potency by targeting multiple pathways (caffeinol/hypothermia). Hopefully, one or more of these approaches, or some even more effective approach to cytoprotection will prove effective. However, careful and thorough preclinical testing showing robust benefit in multiple labs and models with clinically realistic treatment delay, and carefully conducted phase 1 and 2 trials showing that neuroprotective doses can be achieved in stroke patients without unacceptable toxicity, should be required before committing valuable resources to more large phase 3 studies.
